Dr. Reddy’s Laboratories (NYSE:RDY) commences the U.S. commercial launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg and 54 mg, a therapeutic equivalent generic version of Johnson & Johnson’s (NYSE:JNJ) ADHD med Concerta (methylphenidate Hydrochloride) Extended-Release Tablets, 18 mg, 27 mg, 36 mg, and 54 mg.
Per IQVIA, the U.S. market is ~$1.16B.
https://seekingalpha.com/news/3611343-dr-reddys-launches-generic-concerta-in-u-
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.